CompletedPhase 4NCT01330108
Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension
Studying Idiopathic pulmonary arterial hypertension
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Alabama at Birmingham
- Principal Investigator
- Robert C Bourge, MDUniverisity of Alabama at Birmingham
- Intervention
- ambrisentan(drug)
- Enrollment
- 32 enrolled
- Eligibility
- 19 years · All sexes
- Timeline
- 2011 – 2012
Study locations (1)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01330108 on ClinicalTrials.govOther trials for Idiopathic pulmonary arterial hypertension
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNANCT06829589Retrieval of Economic Incentives and Information on Quality-of-care Indicators in Primary CareFundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
- RECRUITINGNANCT06605794FreeFlow Percutaneous Atrial Septal Shunt for IPAHShanghai Zhongshan Hospital
- ACTIVE NOT RECRUITINGNCT05723185Primary Care-Hospital Embedding: a Prospective, Multicentric, Observational StudyRovere Querini Patrizia
- RECRUITINGNANCT05584722Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible IndividualsVanderbilt University Medical Center
- ACTIVE NOT RECRUITINGPHASE2NCT05679570Satralizumab in the Treatment of Pulmonary Arterial Hypertension (SATISFY-JP Trial)International University of Health and Welfare
- RECRUITINGNCT04756076Study Roles of Heavy Metals and Essential Metal Dyshomeostasis in Pulmonary Arterial Hypertension PatientsJiapeng Huang
See all trials for Idiopathic pulmonary arterial hypertension →